During the corresponding time, Integra Lifesciences Holdings Corp recorded a revenue increase by 0.76 % year on year, sequentially revenue grew by 6.85 %. While revenue at the Integra Lifesciences Holdings Corp's corporate clients
Integra Lifesciences Holdings's Comment on Sales, Marketing and Customers
The company operates in international markets and regularly interacts with healthcare professionals who may be classified as foreign officials under the U.S. Foreign Corrupt Practices Act of 1977 and other international anti-bribery laws, including the UK Anti-Bribery Act. Its medical device products are subject to regulatory requirements and oversight by the U.S. Food and Drug Administration (FDA) and comparable governmental agencies in other countries. This oversight includes reporting obligations, recalls, and quality assurance procedures. Compliance with multiple regulators and various centers within the FDA contributes to manufacturing complexity and cost. The company may initiate product recalls or withdrawals voluntarily or as mandated by regulators to address safety or performance concerns.
News about Integra Lifesciences Holdings Corp Contracts
In a development that has drawn considerable scrutiny, Grabar Law Office announced it is investigating potential breaches of fiduciary duty by the Board of Directors at Integra LifeSciences Holdings Corporation (NASDAQ: IART). This investigation, revealed on March 22, 2025, raises critical questions about the company s governance practices and may have significant implications for its shareholders. Understanding the ContextIntegra LifeSciences Holdings Corporation is a prominent player in the medical technology space, specializing in regenerative medicine and surgical solutions. As a publicly traded company with a robust shareholder base, it is imperative that the company s Board acts in the best interest of...
Integra LifeSciences: Revolutionizing Intracranial Pressure Monitoring at AANS Annual Scientific MeetingChicago, Illinois - The American Association of Neurological Surgeons (AANS) Annual Scientific Meeting is set to witness a groundbreaking advancement in the field of intracranial pressure (ICP) monitoring. Integra LifeSciences, a leading global medical technology company, will unveil their cutting-edge CereLink ICP Monitoring System at booth 655. This state-of-the-art device offers a promising solution to the challenges faced by neurosurgeons in accurately measuring and managing ICP levels in patients.Intracranial pressure refers to the pressure inside the skull and brain tissues. Patients suffering from t...
Integra LifeSciences Revolutionizes Surgical Procedures with the Launch of MicroMatrix FlexIntegra LifeSciences, a leading global medical technology company, has announced the introduction of MicroMatrix Flex, a cutting-edge system designed to provide convenient access to hard-to-reach areas during complex surgical cases. This novel system combines the flexibility of its tip with the delivery of the flowable version of the revolutionary Urinary Bladder Matrix (UBM) technology, enhancing surgical precision and improving patient outcomes.The MicroMatrix Flex system s standout feature lies in its flexible tip, allowing surgeons to navigate challenging anatomical structures with ease. This flexible design enable...
Integra Lifesciences Holdings’s Comment on Sales, Marketing and Customers
The company operates in international markets and regularly interacts with healthcare professionals who may be classified as foreign officials under the U.S. Foreign Corrupt Practices Act of 1977 and other international anti-bribery laws, including the UK Anti-Bribery Act. Its medical device products are subject to regulatory requirements and oversight by the U.S. Food and Drug Administration (FDA) and comparable governmental agencies in other countries. This oversight includes reporting obligations, recalls, and quality assurance procedures. Compliance with multiple regulators and various centers within the FDA contributes to manufacturing complexity and cost. The company may initiate product recalls or withdrawals voluntarily or as mandated by regulators to address safety or performance concerns.
Sources:
Integra Lifesciences Holdings Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Integra Lifesciences Holdings Corp’s corporate clients.
For your research, we’ve provided 9 tables on Integra Lifesciences Holdings Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
141.47 %